FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2958974345> ?p ?o ?g. }

• W2958974345 abstract "Abstract Introduction Rifabutin, a rifamycin of equivalent potency to rifampicin, has several advantages in its pharmacokinetic and toxicity profile, particularly in HIV co‐infected patients on combined antiretroviral therapy (cART). In this commentary, we evaluate evidence supporting increased global use of rifabutin and highlight key recommendations for action. Discussion Although extrapolation of data from HIV uninfected patients would suggest non‐inferiority, there has been no randomized controlled study comparing rifabutin versus rifampicin in the outcomes of relapse‐free cure, in drug susceptible tuberculosis (TB), in HIV co‐infected patients on currently utilized cART regimens or in paediatric populations. An important advantage of rifabutin is that compared to the dose adjustments required with rifampicin, it can be co‐administered with the integrase strand transfer inhibitors raltegravir or dolutegravir without the need for dose adjustments. This strategy would be easier to implement in a programmatic setting and would save costs. We have assessed cost incentives to utilize rifabutin and have estimated generic costs for a range of rifabutin dosage scenarios. Where facilities are present for drug re‐challenge and monitoring for drug toxicity and cross‐reactivity, rifabutin offers a switch alternative for adverse drug reactions (ADR)s attributed to rifampicin. This would negate the need to prolong treatment in the absence of a rifamycin as part of short‐course multidrug therapy. There is evidence of incomplete cross‐resistance to rifampicin and rifabutin. Rifabutin may be useful in rifampicin‐resistant TB, in an estimated 20% of cases, based on phenotypic or genotypic rifabutin susceptibility testing. Conclusions Rifabutin should be available globally as a first‐line rifamycin in HIV co‐infected individuals and as a switch option in cases of rifampicin associated ADRs. Further studies are needed to ascertain the utility of rifabutin in rifampicin‐resistant rifabutin‐susceptible TB." @default.
• W2958974345 created "2019-07-23" @default.
• W2958974345 creator A5012931164 @default.
• W2958974345 creator A5041869752 @default.
• W2958974345 creator A5048050447 @default.
• W2958974345 creator A5060462160 @default.
• W2958974345 creator A5085879380 @default.
• W2958974345 date "2019-07-01" @default.
• W2958974345 modified "2023-10-14" @default.
• W2958974345 title "Global access of rifabutin for the treatment of tuberculosis – why should we prioritize this?" @default.
• W2958974345 cites W1501009669 @default.
• W2958974345 cites W1546289395 @default.
• W2958974345 cites W1835214804 @default.
• W2958974345 cites W1894923527 @default.
• W2958974345 cites W1929000320 @default.
• W2958974345 cites W1970755954 @default.
• W2958974345 cites W1975455625 @default.
• W2958974345 cites W1978353805 @default.
• W2958974345 cites W1979481909 @default.
• W2958974345 cites W1985770040 @default.
• W2958974345 cites W2008297056 @default.
• W2958974345 cites W2009034388 @default.
• W2958974345 cites W2017128124 @default.
• W2958974345 cites W2025055730 @default.
• W2958974345 cites W2026717100 @default.
• W2958974345 cites W2044330754 @default.
• W2958974345 cites W2067516271 @default.
• W2958974345 cites W2083674054 @default.
• W2958974345 cites W2083929663 @default.
• W2958974345 cites W2087594116 @default.
• W2958974345 cites W2089663335 @default.
• W2958974345 cites W2099714096 @default.
• W2958974345 cites W2100105241 @default.
• W2958974345 cites W2105634155 @default.
• W2958974345 cites W2111957794 @default.
• W2958974345 cites W2116105908 @default.
• W2958974345 cites W2120343562 @default.
• W2958974345 cites W2134538141 @default.
• W2958974345 cites W2147425587 @default.
• W2958974345 cites W2149008169 @default.
• W2958974345 cites W2156181775 @default.
• W2958974345 cites W2160104000 @default.
• W2958974345 cites W2163156439 @default.
• W2958974345 cites W2170680962 @default.
• W2958974345 cites W2170817647 @default.
• W2958974345 cites W2304970015 @default.
• W2958974345 cites W233147817 @default.
• W2958974345 cites W2336284588 @default.
• W2958974345 cites W2341048433 @default.
• W2958974345 cites W2401515916 @default.
• W2958974345 cites W2493096117 @default.
• W2958974345 cites W2557361187 @default.
• W2958974345 cites W2568393739 @default.
• W2958974345 cites W2571790243 @default.
• W2958974345 cites W2605856369 @default.
• W2958974345 cites W2756268815 @default.
• W2958974345 cites W2766703497 @default.
• W2958974345 cites W2774825923 @default.
• W2958974345 cites W2786620864 @default.
• W2958974345 cites W2791308452 @default.
• W2958974345 cites W2912155276 @default.
• W2958974345 cites W2912724950 @default.
• W2958974345 cites W2918499676 @default.
• W2958974345 cites W2931722970 @default.
• W2958974345 cites W2958974345 @default.
• W2958974345 cites W3151488112 @default.
• W2958974345 cites W367645933 @default.
• W2958974345 cites W4300580349 @default.
• W2958974345 doi "https://doi.org/10.1002/jia2.25333" @default.
• W2958974345 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6637439" @default.
• W2958974345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31318176" @default.
• W2958974345 hasPublicationYear "2019" @default.
• W2958974345 type Work @default.
• W2958974345 sameAs 2958974345 @default.
• W2958974345 citedByCount "16" @default.
• W2958974345 countsByYear W29589743452020 @default.
• W2958974345 countsByYear W29589743452021 @default.
• W2958974345 countsByYear W29589743452022 @default.
• W2958974345 countsByYear W29589743452023 @default.
• W2958974345 crossrefType "journal-article" @default.
• W2958974345 hasAuthorship W2958974345A5012931164 @default.
• W2958974345 hasAuthorship W2958974345A5041869752 @default.
• W2958974345 hasAuthorship W2958974345A5048050447 @default.
• W2958974345 hasAuthorship W2958974345A5060462160 @default.
• W2958974345 hasAuthorship W2958974345A5085879380 @default.
• W2958974345 hasBestOaLocation W29589743451 @default.
• W2958974345 hasConcept C126322002 @default.
• W2958974345 hasConcept C142724271 @default.
• W2958974345 hasConcept C2776306059 @default.
• W2958974345 hasConcept C2776409635 @default.
• W2958974345 hasConcept C2776962512 @default.
• W2958974345 hasConcept C2778607973 @default.
• W2958974345 hasConcept C2780867798 @default.
• W2958974345 hasConcept C2781069245 @default.
• W2958974345 hasConcept C501593827 @default.
• W2958974345 hasConcept C71924100 @default.
• W2958974345 hasConcept C86803240 @default.
• W2958974345 hasConcept C89423630 @default.
• W2958974345 hasConcept C98274493 @default.
• W2958974345 hasConceptScore W2958974345C126322002 @default.

• next